Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful launch of Ocrevus for the treatment of two forms of multiple sclerosis. Based on our half-year performance, we raised the outlook for the full-year to mid-single digit sales growth.”
Syncona has once again proven its commitment to gene therapy start-up, Freeline Therapeutics with a £85 million investment from the £88 million series B funding round. Freeline’s main focus is on gene therapy for Haemophilia B and Farby disease and this latest cash injection ensures Syncosa’s majority stake in the startup.
In the first quarter of 2018, Swiss pharmaceuticals and diagnostics player Roche group’s sales rose by 6% to CHF 13.6 billion. Sales in the pharma division increased by 7% CHF 10.7 billion mainly by strong growth in Ocrevus and Perjeta.
Takeda is considering making a bold move for Shire, after announcing, as per UK regulations, that it may make an approach for the company.
Sanofi will launch public offers to acquire all shares, including ADSs, warrants and convertible bonds of Ablynx. News of the deal will no doubt come as a great disappointment to Novo Nordisk, which recently stepped up its efforts to buy Ablynx with a second offer valued at around 2.6 billion euros.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.